Description

Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate for the management of urothelial carcinoma[1][2].–80°C, protect from light-Applications-Cancer-programmed cell death-Formula-N/A-Citation–References-[1]Halford Z, et al. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. Ann Pharmacother. 2021 Jun;55(6):772-782.|[2]Chang E, et al. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. Clin Cancer Res. 2021 Feb 15;27(4):922-927.-CASNumber-1346452-25-2-MolecularWeight-152000 (average)-Compound Purity-99.74-SMILES-[Enfortumab vedotin-ejfv (solution)]-Research_Area-cancer-Solubility-10 mM in DMSO-Target-Antibody-Drug Conjugates (ADCs);Nectin-4-Isoform–Pathway-Antibody-drug Conjugate/ADC Related;Immunology/Inflammation-MCE Product type-ADC Related